Clinical Trial Update: Enteric Coated Myfortic for Liver Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating enteric-coated mycophenolate mofetil (Myfortic) for liver transplant recipients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation

Drugs mentioned

• Myfortic (enteric-coated mycophenolate mofetil) (mycophenolate mofetil)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Liver Transplantation | Phase 4 | Status: WITHDRAWN